Deutsche Bank AG Acquires 891,921 Shares of Zoetis Inc. $ZTS

Deutsche Bank AG lifted its holdings in Zoetis Inc. (NYSE:ZTS) by 19.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,558,183 shares of the company’s stock after purchasing an additional 891,921 shares during the quarter. Deutsche Bank AG’s holdings in Zoetis were worth $699,331,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Global Wealth Strategies & Associates bought a new stake in shares of Zoetis in the fourth quarter worth $25,000. Lodestone Wealth Management LLC bought a new stake in shares of Zoetis in the fourth quarter worth $30,000. KERR FINANCIAL PLANNING Corp bought a new stake in shares of Zoetis in the third quarter worth $31,000. Holos Integrated Wealth LLC bought a new stake in shares of Zoetis in the fourth quarter worth $32,000. Finally, Elyxium Wealth LLC bought a new stake in shares of Zoetis in the fourth quarter worth $32,000. Institutional investors own 92.80% of the company’s stock.

Insider Buying and Selling

In other Zoetis news, Director Frank A. Damelio purchased 6,650 shares of the stock in a transaction that occurred on Wednesday, May 13th. The shares were acquired at an average cost of $75.39 per share, with a total value of $501,343.50. Following the completion of the transaction, the director owned 21,458 shares in the company, valued at $1,617,718.62. The trade was a 44.91% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Paul Bisaro purchased 2,000 shares of the stock in a transaction that occurred on Wednesday, May 13th. The shares were acquired at an average cost of $75.88 per share, for a total transaction of $151,760.00. Following the completion of the transaction, the director owned 27,862 shares of the company’s stock, valued at $2,114,168.56. This trade represents a 7.73% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders have acquired 11,650 shares of company stock valued at $886,384. 0.22% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of analysts have recently commented on ZTS shares. Argus reissued a “hold” rating on shares of Zoetis in a research report on Wednesday, May 27th. Citigroup cut their price target on shares of Zoetis from $145.00 to $112.00 and set a “buy” rating for the company in a research note on Monday, May 18th. William Blair reissued an “outperform” rating on shares of Zoetis in a research report on Monday, March 2nd. Wall Street Zen downgraded shares of Zoetis from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Finally, BTIG Research reissued a “buy” rating and issued a $160.00 price objective on shares of Zoetis in a research report on Thursday, February 26th. Six investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $133.92.

Zoetis News Summary

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Zoetis received U.K. approval for Lenivia, a long-acting osteoarthritis pain treatment for dogs, which could help expand its companion-animal business and support future product revenue. Zoetis (ZTS) Receives UK Approval for Long-Acting Osteoarthritis Pain Therapy Lenivia
• Neutral Sentiment: Analyst commentary noted Stifel lowered its price target on Zoetis to $95 from $105 while keeping a Hold rating, reinforcing a more cautious near-term view on the stock. Here’s What Analysts Are Saying About Zoetis Inc. (ZTS)
• Negative Sentiment: Multiple law firms announced or reiterated class-action lawsuits and lead-plaintiff deadlines against Zoetis, alleging investor harm tied to alleged securities-law violations during the Jan. 14, 2025 to May 6, 2026 period, which may pressure the shares. INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zoetis Inc. of Class Action Lawsuit and Upcoming Deadlines – ZTS
• Negative Sentiment: Additional securities-fraud notices from firms including Schall, Gross, Rosen, Glancy Prongay, Levi & Korsinsky, and others keep legal overhang front and center, increasing headline risk for Zoetis. ZTS Investors Have Opportunity to Lead Zoetis Inc. Securities Fraud Lawsuit with the Schall Law Firm

Zoetis Price Performance

Shares of ZTS opened at $82.05 on Wednesday. The firm has a market capitalization of $34.40 billion, a PE ratio of 13.61, a PEG ratio of 1.23 and a beta of 0.75. The company’s 50-day moving average is $99.13 and its 200-day moving average is $115.00. Zoetis Inc. has a fifty-two week low of $72.38 and a fifty-two week high of $168.83. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.60 by ($0.07). The company had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. Zoetis’s revenue for the quarter was up 2.9% compared to the same quarter last year. During the same period in the previous year, the company earned $1.48 earnings per share. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Equities analysts forecast that Zoetis Inc. will post 6.88 EPS for the current year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be given a $0.53 dividend. The ex-dividend date of this dividend is Monday, July 20th. This represents a $2.12 annualized dividend and a dividend yield of 2.6%. Zoetis’s dividend payout ratio is presently 35.16%.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.